Diethylamine/nitric oxide (no) adduct, an no donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs

Paula Vanderford, Jackson Wong, Roger Chang, Larry K. Keefer, Scott J. Soifer, Jeffrey R. Fineman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Nitric oxide (NO), a labile humoral factor produced by vascular endothelial cells, is a potent vasodilator and an important mediator of pulmonary vascular tone. Nucleophile/NO adducts are a new class of compounds that spontaneously and predictively release NO. We investigated the hemodynamic effects of intravenous (i.v.) infusions of a recently developed NO-donor drug, the diethylamine-nitric oxide adduct (DEA/NO), in 17 intact newborn lambs. At rest, DEA/NO (1–2 H-g kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 10.6 ± 8.6 to 21.2 ± 7.9%, p <0.05) and systemic arterial pressure (from 13.2 ± 11.7 to 31.0 ± 15.4%, p <0.05). Similarly, during pulmonary hypertension induced by infusion of U46619, DEA/NO (0.5–2.0 μg kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 7.3 ± 5.6 to 24.1 ± 13.3%, p <0.05) and systemic arterial pressure (from 2.2 ± 3.8 to 20.3 ± 12.9%, p <0.05). Cardiac output (CO), heart rate (HR), systemic arterial blood gases, and pH were unchanged; atrial pressures decreased at higher doses. Equimolar infusions of S-nitroso-N-acetylpenicillamine, nitroglycerin (NTG), and sodium nitro-prusside (SNP) produced similar decreases in pulmonary and systemic arterial pressure. The nucleophile/NO adducts are potent vasodilators; their predictable and quantitative release of NO make them potentially useful research tools. In addition, because these compounds may decrease the incidence of tolerance and the risk from toxic metabolites associated with use of other nitrova-sodilators, they may be clinically useful.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalJournal of Cardiovascular Pharmacology
Volume23
Issue number1
StatePublished - 1994
Externally publishedYes

Fingerprint

Nitric Oxide Donors
Vasodilation
Nitric Oxide
Lung
Arterial Pressure
Vasodilator Agents
S-Nitroso-N-Acetylpenicillamine
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid
Atrial Pressure
diethylamine
Poisons
Nitroglycerin
Pulmonary Hypertension
Intravenous Infusions
Cardiac Output
Blood Vessels
Endothelial Cells
Heart Rate
Gases
Hemodynamics

Keywords

  • Nitric oxide donors
  • Nitrovasodilators
  • Nucleophile/nitric oxide adducts
  • Pulmonary hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Diethylamine/nitric oxide (no) adduct, an no donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. / Vanderford, Paula; Wong, Jackson; Chang, Roger; Keefer, Larry K.; Soifer, Scott J.; Fineman, Jeffrey R.

In: Journal of Cardiovascular Pharmacology, Vol. 23, No. 1, 1994, p. 113-119.

Research output: Contribution to journalArticle

Vanderford, Paula ; Wong, Jackson ; Chang, Roger ; Keefer, Larry K. ; Soifer, Scott J. ; Fineman, Jeffrey R. / Diethylamine/nitric oxide (no) adduct, an no donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs. In: Journal of Cardiovascular Pharmacology. 1994 ; Vol. 23, No. 1. pp. 113-119.
@article{83d69c789e6c4065b9ccf706aee3f6e4,
title = "Diethylamine/nitric oxide (no) adduct, an no donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs",
abstract = "Nitric oxide (NO), a labile humoral factor produced by vascular endothelial cells, is a potent vasodilator and an important mediator of pulmonary vascular tone. Nucleophile/NO adducts are a new class of compounds that spontaneously and predictively release NO. We investigated the hemodynamic effects of intravenous (i.v.) infusions of a recently developed NO-donor drug, the diethylamine-nitric oxide adduct (DEA/NO), in 17 intact newborn lambs. At rest, DEA/NO (1–2 H-g kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 10.6 ± 8.6 to 21.2 ± 7.9{\%}, p <0.05) and systemic arterial pressure (from 13.2 ± 11.7 to 31.0 ± 15.4{\%}, p <0.05). Similarly, during pulmonary hypertension induced by infusion of U46619, DEA/NO (0.5–2.0 μg kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 7.3 ± 5.6 to 24.1 ± 13.3{\%}, p <0.05) and systemic arterial pressure (from 2.2 ± 3.8 to 20.3 ± 12.9{\%}, p <0.05). Cardiac output (CO), heart rate (HR), systemic arterial blood gases, and pH were unchanged; atrial pressures decreased at higher doses. Equimolar infusions of S-nitroso-N-acetylpenicillamine, nitroglycerin (NTG), and sodium nitro-prusside (SNP) produced similar decreases in pulmonary and systemic arterial pressure. The nucleophile/NO adducts are potent vasodilators; their predictable and quantitative release of NO make them potentially useful research tools. In addition, because these compounds may decrease the incidence of tolerance and the risk from toxic metabolites associated with use of other nitrova-sodilators, they may be clinically useful.",
keywords = "Nitric oxide donors, Nitrovasodilators, Nucleophile/nitric oxide adducts, Pulmonary hypertension",
author = "Paula Vanderford and Jackson Wong and Roger Chang and Keefer, {Larry K.} and Soifer, {Scott J.} and Fineman, {Jeffrey R.}",
year = "1994",
language = "English (US)",
volume = "23",
pages = "113--119",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Diethylamine/nitric oxide (no) adduct, an no donor, produces potent pulmonary and systemic vasodilation in intact newborn lambs

AU - Vanderford, Paula

AU - Wong, Jackson

AU - Chang, Roger

AU - Keefer, Larry K.

AU - Soifer, Scott J.

AU - Fineman, Jeffrey R.

PY - 1994

Y1 - 1994

N2 - Nitric oxide (NO), a labile humoral factor produced by vascular endothelial cells, is a potent vasodilator and an important mediator of pulmonary vascular tone. Nucleophile/NO adducts are a new class of compounds that spontaneously and predictively release NO. We investigated the hemodynamic effects of intravenous (i.v.) infusions of a recently developed NO-donor drug, the diethylamine-nitric oxide adduct (DEA/NO), in 17 intact newborn lambs. At rest, DEA/NO (1–2 H-g kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 10.6 ± 8.6 to 21.2 ± 7.9%, p <0.05) and systemic arterial pressure (from 13.2 ± 11.7 to 31.0 ± 15.4%, p <0.05). Similarly, during pulmonary hypertension induced by infusion of U46619, DEA/NO (0.5–2.0 μg kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 7.3 ± 5.6 to 24.1 ± 13.3%, p <0.05) and systemic arterial pressure (from 2.2 ± 3.8 to 20.3 ± 12.9%, p <0.05). Cardiac output (CO), heart rate (HR), systemic arterial blood gases, and pH were unchanged; atrial pressures decreased at higher doses. Equimolar infusions of S-nitroso-N-acetylpenicillamine, nitroglycerin (NTG), and sodium nitro-prusside (SNP) produced similar decreases in pulmonary and systemic arterial pressure. The nucleophile/NO adducts are potent vasodilators; their predictable and quantitative release of NO make them potentially useful research tools. In addition, because these compounds may decrease the incidence of tolerance and the risk from toxic metabolites associated with use of other nitrova-sodilators, they may be clinically useful.

AB - Nitric oxide (NO), a labile humoral factor produced by vascular endothelial cells, is a potent vasodilator and an important mediator of pulmonary vascular tone. Nucleophile/NO adducts are a new class of compounds that spontaneously and predictively release NO. We investigated the hemodynamic effects of intravenous (i.v.) infusions of a recently developed NO-donor drug, the diethylamine-nitric oxide adduct (DEA/NO), in 17 intact newborn lambs. At rest, DEA/NO (1–2 H-g kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 10.6 ± 8.6 to 21.2 ± 7.9%, p <0.05) and systemic arterial pressure (from 13.2 ± 11.7 to 31.0 ± 15.4%, p <0.05). Similarly, during pulmonary hypertension induced by infusion of U46619, DEA/NO (0.5–2.0 μg kg-1 min-1) produced dose-dependent decreases in mean pulmonary (from 7.3 ± 5.6 to 24.1 ± 13.3%, p <0.05) and systemic arterial pressure (from 2.2 ± 3.8 to 20.3 ± 12.9%, p <0.05). Cardiac output (CO), heart rate (HR), systemic arterial blood gases, and pH were unchanged; atrial pressures decreased at higher doses. Equimolar infusions of S-nitroso-N-acetylpenicillamine, nitroglycerin (NTG), and sodium nitro-prusside (SNP) produced similar decreases in pulmonary and systemic arterial pressure. The nucleophile/NO adducts are potent vasodilators; their predictable and quantitative release of NO make them potentially useful research tools. In addition, because these compounds may decrease the incidence of tolerance and the risk from toxic metabolites associated with use of other nitrova-sodilators, they may be clinically useful.

KW - Nitric oxide donors

KW - Nitrovasodilators

KW - Nucleophile/nitric oxide adducts

KW - Pulmonary hypertension

UR - http://www.scopus.com/inward/record.url?scp=0028055218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028055218&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 113

EP - 119

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -